ASCO 2015 Highlights

Clinical Correlation and Frequency of PD-L1 Expression in EGFR-Mutant and ALK-Rearranged NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Results from POPLAR: Efficacy, Safety, and Predictive Biomarker Results From a Randomized Phase 2 Study Comparing MPDL3280A vs Docetaxel in NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Checkmate 017: A Phase 3 Study of Nivolumab vs Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Final Overall Survival Results of the Phase 3 PROCLAIM Trial

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Necitumumab in Metastatic Squamous NSCLC: Establishing a Value-Based Cost

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Phase 1-1B Trial of Tivantinib in Combination with Carboplatin and Pemetrexed as First-Line Treatment in Patients with Advanced Nonsquamous NSCLC or Malignant Pleural Mesothelioma

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

A Phase 3B/4 Safety Trial of Nivolumab (NIVO) in Patients with Advanced or Metastatic NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Phase 3 Trial (Checkmate 057) of Nivolumab (NIVO) Versus Docetaxel (DOC) In Advanced Non Squamous Cell (Non-SQ) NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

The Mission of the Association for Value-Based Cancer Care

The Mission of the Association for Value-Based Cancer Care

By Burt Zweigenhaft, PhD, D.Litt

Program Chair, Burt Zweigenhaft, describes the main mission of the Association for Value-Based Cancer Care.

AVBCC Essential for Quality Practices

AVBCC Essential for Quality Practices

By Vicki Kennedy, LCSW

Vicki Kennedy supports the position that professional associations are essential to quality practices. The Association for Value-Based Cancer Care (AVBCC) has been critical in advancing the discussion and solutions surrounding value-based care.

Page 195 of 329